Suomi - suomi - Fimea (Suomen lääkevirasto)

sanoswiss uab - mometasone furoate monohydrate - nenäsumute, suspensio - 50 mikrog/annos - mometasoni

Euroopan unioni - suomi - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - prostatiset kasvaimet - diagnostiset radiofarmaseuttiset valmisteet - tämä lääkevalmiste on tarkoitettu vain diagnostiseen käyttöön. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).